MMP9 and Stroke: Those subjects having MMP9 R668Q common GG genotype randomized to chlorthalidone had a slightly increased risk of stroke over those with the same genotype randomized to amlodipine (HR = 1.08), whereas participants with the AA genotype had a 3.65-fold increased risk of stroke when randomized to chlorthalidone versus amlodipine.